GANX Gain Therapeutics Inc

Price (delayed)

$1.84

Market cap

$80.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$67.83M

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate, GT-02287 is currently being evaluated for the treatment ...

Highlights
The EPS has grown by 21% YoY and by 14% from the previous quarter
Gain Therapeutics's debt has decreased by 10% YoY and by 9% QoQ
GANX's quick ratio has soared by 195% YoY but it is down by 11% QoQ
The net income is down by 8% year-on-year but it is up by 5% since the previous quarter
GANX's equity is down by 19% since the previous quarter

Key stats

What are the main financial stats of GANX

GANX stock price

How has the Gain Therapeutics stock price performed over time
Intraday
-5.64%
1 week
6.98%
1 month
-8.23%
1 year
5.14%
YTD
-42.86%
QTD
-9.36%

Financial performance

How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.29M
Net income
-$20.11M
Gross margin
N/A
Net margin
N/A
GANX's operating income is down by 12% YoY but it is up by 2.1% QoQ
The net income is down by 8% year-on-year but it is up by 5% since the previous quarter

Price vs fundamentals

How does GANX's price correlate with its fundamentals

Growth

What is Gain Therapeutics's growth rate over time

Valuation

What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
6.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 21% YoY and by 14% from the previous quarter
The stock's price to book (P/B) is 42% more than its 5-year quarterly average of 5.2 but 3% less than its last 4 quarters average of 7.6
GANX's equity is down by 19% since the previous quarter

Efficiency

How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has increased by 44% YoY and by 20% QoQ
GANX's return on assets is up by 24% year-on-year and by 13% since the previous quarter

Dividends

What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GANX.

Financial health

How did Gain Therapeutics financials performed over time
GANX's quick ratio has soared by 195% YoY but it is down by 11% QoQ
GANX's current ratio has surged by 144% year-on-year but it is down by 7% since the previous quarter
Gain Therapeutics's debt is 95% lower than its equity
GANX's debt to equity has dropped by 72% year-on-year
GANX's equity is down by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.